title: Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity.
abstract: This trial was conducted to study the frequency of the slow acetylator phenotype in asymptomatic HIV patients having no previous reaction to sulfa-drugs, and to compare this frequency with the frequency found in healthy controls. Results show that HIV alone is not capable of modifying the acetylator phenotype; the prevalence of slow acetylator phenotype is the same in immune competent subjects and HIV-positive patients. It is more common in HIV-positive patients with a CD4+ lymphocyte count of less than 200 mm-3.
authors.forename: T
authors.initials: T
authors.lastname: Quirino
authors.forename: P
authors.initials: P
authors.lastname: Bonfanti
authors.forename: M
authors.initials: M
authors.lastname: Arcidiacono
authors.forename: L
authors.initials: L
authors.lastname: Pusterla
authors.forename: A
authors.initials: A
authors.lastname: Cagni
authors.forename: F
authors.initials: F
authors.lastname: Scaglione
authors.forename: F
authors.initials: F
authors.lastname: Milazzo
mesh_terms: D000107:Acetylation; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000235:genetics* / Q000378:metabolism; D006679:HIV Seropositivity; D006801:Humans; D007700:Kinetics; D008297:Male; D010641:Phenotype; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination